Ceftazidime-Avibactam Hepatic Safety Profile

Introduction to Hepatic Safety

• The American College of Clinical Pharmacology and other guideline societies recommend ceftazidime-avibactam as a safe option for treating carbapenem-resistant Enterobacterales infections, with no significant liver enzyme elevation observed in clinical studies 1

Evidence from Clinical Studies

• No differences were observed in liver function tests between patients receiving ceftazidime-avibactam and comparator antimicrobial groups, indicating a favorable hepatic safety profile 1
• The frequency and profile of adverse effects, including hepatic parameters, were equivalent between treatment groups, supporting the use of ceftazidime-avibactam in patients with normal liver function 1
• Studies in critically ill, mechanically ventilated patients with CRE infections showed similar hepatic safety profiles, suggesting that ceftazidime-avibactam can be used safely in this population 1

Clinical Monitoring Recommendations

• Baseline liver function testing is reasonable but not mandated by guidelines for patients receiving ceftazidime-avibactam, unless other risk factors are present 1
• If unexplained fever, malaise, vomiting, jaundice, or clinical deterioration occur during treatment, liver function should be checked, as recommended by the European Respiratory Society 3

Comparative Context with Other Antibiotics

• Tigecycline-based regimens have documented hepatotoxicity concerns that are not seen with ceftazidime-avibactam, making ceftazidime-avibactam a safer alternative for treating resistant infections 1

Key Clinical Takeaway

• The Infectious Diseases Society of America and other guideline societies recommend that ceftazidime-avibactam should not be avoided or require special hepatic monitoring based on concerns about liver enzyme elevation, as guideline-level evidence demonstrates equivalent hepatic safety to comparator regimens 1, 2